Trials / Not Yet Recruiting
Not Yet RecruitingNCT07444684
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
A Phase II Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 Injection in Adult Patients With Pyoderma Gangrenosum
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1139 Injection | SHR-1139 injection. |
Timeline
- Start date
- 2026-03-05
- Primary completion
- 2027-06-01
- Completion
- 2028-04-01
- First posted
- 2026-03-03
- Last updated
- 2026-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07444684. Inclusion in this directory is not an endorsement.